Company description::
Investorideas.com Global Investor Portal Features Biotech Investor Research as Biotech Makes Recent Headlines Profiled Company Genetronics Inc., Positioned With Unique Cancer Therapy
POINT ROBERTS, Wash., Apr 30, 2004 – Investorideas.com is pleased to provide investors following the Biotech sector resources including news, industry research and a list of public companies in the sector. The Biotech sector has attracted serious investor attention with stocks realizing one-day gains not seen in the market for years. On April 26th, OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) went up $52 as it announced that a Phase III study of Tarceva(TM) (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva(TM) living longer than those in the placebo arm of the study. This is an indicator of the urgent need to find therapies and solutions in cancer treatment as the lifetime probability of being diagnosed with cancer, for both men and women, has increased to dramatic rates.
Genetronics, Inc. (GEB): Unique cancer therapy can selectively kill cancerous cells while preserving healthy tissue
Genetronics, Inc. is a leader in electroporation therapy with over 200 patents issued, allowed, or pending. Genetronics, Inc. utilizes its proprietary electroporation technology for the targeted intracellular delivery of therapeutic materials, concentrating on drugs, DNA vaccines, and gene therapies. In oncology, it has initiated Phase III clinical trials for the treatment of recurrent head & neck cancer, and has marketing approval in Europe. First sales are planned for 2005. In gene therapy, it has several collaborations with major biotechnology and pharmaceutical companies, such as Chiron, for the delivery of therapeutic genes or vaccines using electroporation. www.genetronics.com
Our Current List of Stocks:
http://www.investorideas.com/Research/Biotech,PharmaStocks.asp
The site does not make stock recommendations but offers a unique free information portal for investors to research news, articles, and recent research.
Investorideas.com Biotech Research Page:
http://www.investorideas.com/Research/Industries/Biotech.asp
100 Years of Advances Against Cancer:
http://www.nci.nih.gov/newscenter/100-yrs
Cancer Statistics Presentation 2004
http://www.cancer.org/docroot/pro/content/pro_1_1_Cancer_Statistics_2004_presentation.asp
Additional Featured Biotech Company:
Aethlon Medical, Inc. (OTCBB: AEMD) is pioneering the development of viral filtration devices that rapidly reduce the presence of infectious disease and toxins in the body. Aethlon has published compelling human blood studies of the Hemopurifier(TM) to treat HIV/AIDS and Hepatitis-C (HCV), and most recently, has announced that it is developing pathogen filtration devices to treat infectious agents used in biological warfare and terrorism. The Hemopurifier is a proprietary platform technology that converges the established scientific principles of affinity chromatography and hemodialysis as a means to augment the immune response of clearing viruses and toxins from the blood before cell and organ infection can occur.
On March 4, 2004, Aethlon announced a cooperative agreement with the National Center for Biodefense (NCBD) at George Mason University. Under the agreement, Aethlon and the NCBD will collaborate to develop pathogen and toxin filtration devices designed to protect the lives of U.S. Military personnel exposed to infectious agents as a result of biological warfare.
Research Report: www.stocksontheweb.com/aemd.htm
ECON Corporate Services, offer clients customized, comprehensive corporate IR/PR programs, corporate strategies and industry research within specific sectors. AEMD is currently a paying client of Investorideas.com
Disclaimer: www.investorideas.com/About/News/Clientspecifics.asp
ECON Investor Relations, Inc., (ECON Corporate Services) is a privately owned corporate communications company specializing in investor relations, media relations and research in public companies and industry sectors for the investment community. Nothing on the site should be construed as an offer or solicitation to buy or sell any specific products or securities.
For more information contact:
Dawn Van Zant 800-665-0411 Trevor Ruehs 866-730-1151
Email: dvanzant@investorideas.com or truehs@investorideas.com
Web Site: http://www.InvestorIdeas.com
|
